Cravath Partner Mark Greene Featured by Crain’s as a 2024 “Notable Leader in Accounting, Consulting & Law”
December 10, 2024
Cravath partner Mark I. Greene was named to Crain’s New York Business’s inaugural list of “Notable Leaders in Accounting, Consulting & Law,” published on December 9, 2024. The feature honors professionals who “excel in their fields” and “embody the spirit of New York in their creativity and achievement.”
Crain’s highlighted Mark’s responsibilities as Head of Cravath’s Corporate Department and Leader of its International Practice, where he represents multinational industry leaders, emerging companies and entrepreneurs in connection with mergers and acquisitions, corporate governance and securities matters, including advising on cross-border and domestic transactions, private equity deals, complex restructuring transactions and more. The publication recognized in particular his representation of Mylan in its $50 billion combination with Upjohn to form Viatris.
Related Practices & Industries
People
- Photo
-
-
J.D., 1993, University of Pennsylvania Law School
-
B.A., 1989, Cornell University
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
July 29, 2019
Mylan’s $50 Billion Combination with Upjohn, a Division of Pfizer
On July 29, 2019, Mylan N.V. and Pfizer Inc. announced a definitive agreement to combine Mylan with Upjohn, Pfizer's off-patent branded and generic established medicines business, creating a new global pharmaceutical company. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, each Mylan share would be converted into one share of the new company. Pfizer shareholders would own 57% of the combined new company, and Mylan shareholders would own 43%. Cravath is representing Mylan in connection with the transaction.
